(Q37810993)

23 August 2017

title

Imaging cognitive and behavioral symptoms in Parkinson's disease (English)

1 reference

23 August 2017

1 reference

2

0 references

Antonio P Strafella

series ordinal

3

object named as

Antonio P Strafella

1 reference

23 August 2017

Francesca Antonelli

1

1 reference

23 August 2017

publication date

1 December 2010

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1827-1838

1 reference

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Cognitive and motor shifting aptitude disorder in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Planning and spatial working memory in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

What causes mental dysfunction in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Neuropsychological profile of patients with Parkinson's disease without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Dopaminergic modulation of cortical function in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Cognitive function in Parkinson's disease: From description to theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

The functional anatomy of basal ganglia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

A default mode of brain function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

A default mode of brain function: a brief history of an evolving idea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Dysfunction of the default mode network in Parkinson disease: a functional magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Dopamine modulates default mode network deactivation in elderly individuals during the Tower of London task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Neural bases of set-shifting deficits in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Cortical activity in Parkinson's disease during executive processing depends on striatal involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements. A PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Functional imaging studies of non-motoric manifestations of Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson's disease patients: a [I-123]FP-CIT SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Prefrontostriatal connections in relation to cortical architectonic organization in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Evidence for a two-stage model of spatial working memory processing within the lateral frontal cortex: a positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

The cognitive functions of the caudate nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Imaging non-dopaminergic function in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Postural control, gait, and dopamine functions in parkinsonian movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Dissociation in prefrontal cortex of affective and attentional shifts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Dopaminergic suppression of brain deactivation responses during sequence learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

The impact of deep brain stimulation on executive function in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Subthalamic nucleus stimulation affects striato-anterior cingulate cortex circuit in a response conflict task: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Stimulation of STN impairs aspects of cognitive control in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

STN stimulation alters pallidal-frontal coupling during response selection under competition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Stimulation of the subthalamic nucleus and impulsivity: release your horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Neural correlates of STN DBS-induced cognitive variability in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

The neuropsychology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Cognitive deficits in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Risk of dementia in Parkinson's disease: a community-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Clinical diagnostic criteria for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Amyloid beta-peptide and the dementia of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Imaging amyloid deposition in Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Strange bedfellows: a critical view of pathological gambling and addiction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Pathological gambling caused by drugs used to treat Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Imaging dopamine's role in drug abuse and addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Neuropsychiatric symptoms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Stages in the development of Parkinson's disease-related pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

The neuropathologic basis of different clinical subgroups of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Imaging Approaches to Parkinson Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Regional patterns of brain tissue loss associated with depression in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Does subthalamic nucleus stimulation induce apathy in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Neuroanatomical correlates of apathy in Parkinson's disease: A magnetic resonance imaging study using voxel‐based morphometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Visual hallucinations in Parkinson's disease: a review and phenomenological survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Hallucinations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Visual hallucinations in the elderly associated with the use of levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Prospective study of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Metabolic alterations in patients with Parkinson disease and visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Medication-induced hallucination and cerebral blood flow in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Visual hallucination in Parkinson's disease with FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Serotonin 2A receptors and visual hallucinations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Striatal dopamine release during performance of executive functions: A [(11)C] raclopride PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

Prospective prevalence of pathologic gambling and medication association in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.173

21 January 2018

Identifiers

DOI

10.1586/ERN.10.173

1 reference

23 August 2017

1 reference